Related Experiment Video
Updated: Jul 5, 2026
An Orthotopic Mouse Model of Anaplastic Thyroid Carcinoma
Published on: April 17, 2013
TRβ Agonism Induces Tumor Suppression and Enhances Drug Efficacy in Anaplastic Thyroid Cancer in Female Mice
Noelle E Gillis1,2, Lauren M Cozzens1, Emily R Wilson1
1Department of Pharmacology, Larner College of Medicine, University of Vermont, Burlington, VT 05405, USA.
Abstract:
Thyroid hormone receptor beta (TRβ) is a recognized tumor suppressor in numerous solid cancers. The molecular signaling of TRβ has been elucidated in several cancer types through re-expression models. Remarkably, the potential impact of selective activation of endogenous TRβ on tumor progression remains largely unexplored. We used cell-based and in vivo assays to evaluate the effects of the TRβ agonist sobetirome (GC-1) on a particularly aggressive and dedifferentiated cancer, anaplastic thyroid cancer (ATC). Here we report that GC-1 reduced the tumorigenic phenotype, decreased cancer stem-like cell populations, and induced redifferentiation of the ATC cell lines with different mutational backgrounds. Of note, this selective activation of TRβ amplified the effects of therapeutic agents in blunting the aggressive cell phenotype and stem cell growth. In xenograft assays, GC-1 alone inhibited tumor growth and was as effective as the kinase inhibitor, sorafenib. These results indicate that selective activation of TRβ not only induces a tumor suppression program de novo but enhances the effectiveness of anticancer agents, revealing potential novel combination therapies for ATC and other aggressive solid tumors.
Insights
Selective activation of thyroid hormone receptor beta (TRβ) using sobetirome (GC-1) suppressed anaplastic thyroid cancer (ATC) progression. This approach also enhanced existing therapies, suggesting new combination treatments for aggressive cancers.
Area of Science:
- Oncology
- Endocrinology
- Molecular Biology
Background:
- Thyroid hormone receptor beta (TRβ) acts as a tumor suppressor in various solid cancers.
- The role of endogenous TRβ activation in tumor progression is understudied.
- Anaplastic thyroid cancer (ATC) is an aggressive, dedifferentiated cancer.
Purpose of the Study:
- To investigate the effects of the TRβ agonist sobetirome (GC-1) on anaplastic thyroid cancer (ATC).
- To evaluate the potential of selective TRβ activation in suppressing tumor progression and enhancing therapeutic efficacy.
Main Methods:
- Cell-based assays were used to assess tumorigenic phenotype, cancer stem-like cell populations, and redifferentiation.
- In vivo xenograft assays were performed to evaluate tumor growth inhibition.
- The study utilized different ATC cell lines with varying mutational backgrounds.
Main Results:
- Sobetirome (GC-1) reduced the tumorigenic phenotype and cancer stem-like cell populations in ATC cell lines.
- GC-1 induced redifferentiation of ATC cells.
- Selective TRβ activation amplified the effects of therapeutic agents on aggressive cell phenotypes and stem cell growth.
- In xenografts, GC-1 alone inhibited tumor growth, showing efficacy comparable to sorafenib.
Conclusions:
- Selective TRβ activation with GC-1 initiates a tumor suppression program in ATC.
- GC-1 enhances the effectiveness of existing anticancer agents, indicating potential for novel combination therapies.
- This approach holds promise for treating ATC and other aggressive solid tumors.
Related Concept Videos
02:43Mouse Models of Cancer Study
The development of transgenic, knockout, and knock-in mice has led to an exponential increase in their use as model organisms in research,...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase